markets

Claire Yubin Oh1/30/26

Deckers soars on record revenue thanks to Hoka and Ugg demand

Deckers had a lot to celebrate over the holiday period, with the footwear company’s shares up more than 14% as of 6:45 a.m. ET on Friday, after the Hoka and Ugg maker posted record revenue for the quarter ended December 31, 2025. The company notched:

Record revenue of $1.96 billion, ahead of the $1.87 billion forecast by analysts (Bloomberg consensus).
Adjusted earnings per share of $3.33, a whopping 21% higher than the $2.76 predicted by analysts.

Looking ahead, the company also hiked its guidance for the fiscal year ending March 31, 2026, to $5.4 billion to $5.425 billion, up from the $5.35 billion expected in the quarter before.

Deckers’ record revenue and EPS figures were “driven by the significant global demand for UGG and HOKA,” CEO Stefano Caroti said in a press release. Both brands saw “high levels of full-price selling” that resulted in a strong gross margin of 59.8%. Between the two brands, winter favorite Ugg maintained the upper hand with $1.3 billion in revenue, but Hoka saw a whopping 18.5% sales uptick (versus Ugg’s 5%) to $629 million last quarter.

Deckers also shared that the company has now repurchased stock worth $813.5 million in the last nine months, and that it expects its share repurchases to exceed $1 billion for the fiscal year ending March 31, 2026.

More Markets

See all Markets

markets

Max Knoblauch25m

Spectrum-owner Charter Communications is on pace for its worst day ever as broadband numbers and Q1 results disappoint

Cable and broadband company Charter Communications is on pace for its worst-ever trading day on Friday, as investors dump the stock following its Q1 results and forward guidance.

Charter, which owns Spectrum, reported adjusted earnings of $9.17 per share, below Wall Street estimates of $9.96 per share from analysts polled by FactSet. On the company’s earnings call, CFO Jessica Fischer appeared to lower its full-year revenue per user guidance.

“It'll be close either way in terms of whether we end up with net growth,” said Fischer.

The company lost 120,000 internet subscribers in the quarter, deeper than the expected 94,800 and double its loss from the same period last year. That news comes one day after Comcast’s earnings provided a bit of optimism for broadband as a category: the company reported Q1 losses of 65,000, significantly improving from 183,000 losses in the same quarter last year. Comcast is down more than 10%, on pace for its worst day since January 2025.

Google to reportedly invest up to $40 billion in Anthropic

Amazon announced plans to deepen its investment in the Claude developer earlier this week.

Alphabet/Google CEO Sundar Pichai

markets

Nvidia poised to snap longest run without a record close since the AI boom began

The stock price of the company responsible for the brains of the AI boom is finally showing some brawn again.

Nvidia, the world’s most valuable company, is poised to close at a record high for the first time since October 29, 2025, on Friday (if it ends above $207.04).

The AI chip trade is on fire, with the Philadelphia Semiconductor Index slated to deliver its 18th consecutive gain as Intel’s robust results and outlook juice the entire ecosystem. Hyperscalers report earnings next week, and their capex guidance can be thought of as the earnings guidance for Nvidia and other AI suppliers for the quarters to come.

This would end Nvidia’s longest stretch without a record close since the unofficial start of the AI boom (when the chip designer delivered blowout quarterly results in May 2023).

(Sorry if I jinx this!)

markets

J. Edward Moreno2h

Lilly slips after prescriptions for its weight-loss pill come in below expectations in second week

Eli Lilly fell on Friday after prescription data for its new weight-loss pill, Foundayo, showed that it’s having a significantly slower rollout than its top competitor.

The pill was prescribed about 3,700 times in its second week, according to IQVIA data cited by Deutsche Bank analysts, compared to the roughly 8,000 they were expecting. Novo Nordisk’s Wegovy pill, which came out in January, hit over 18,000 prescriptions in its second week.

The FDA approved Foundayo on April 1 and shipments began on April 9. Deutsche analysts noted that Lilly’s GLP-1 injections, which currently outsell Novo’s, also had a slower start.

Lilly fell more than 4% after the numbers were released. Novo Nordisk rose more than 5%.

Intel massive stock move after Q1 earnings report

Intel soars by the most in decades after crushing Q1 earnings

A pretty good day.

Matt Phillips4h

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.

©2026 Sherwood Media, LLC